Alto Neuroscience (ANRO) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Alto Neuroscience, Inc. (ANRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).…

The mean of analysts' price targets for Alto Neuroscience, Inc. (ANRO) points to a 29.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in …

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatri…

Alto Neuroscience, Inc. (NYSE: ANRO - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Friday. The stock has a two hundred day moving average of $24.32 and traded as high a…

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatri…

Alto advances its depression drug pipeline, with key 2027 study results ahead for ALTO-207, ALTO-300 and ALTO-100.…

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatri…

Shares of Alto Neuroscience, Inc. (NYSE: ANRO - Get Free Report) have received a consensus rating of "Moderate Buy" from the eleven analysts that are presently covering the stock, Marketbeat.com reports. One research ana…

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company developing novel precision medicines for neuropsychiatric disorders, today announced…

AWM Investment Company Inc. bought a new position in shares of Alto Neuroscience, Inc. (NYSE: ANRO) during a recent quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 80…

Alto Neuroscience, Inc. (NYSE: ANRO - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Tuesday. The company traded as high as $36.99 and last traded at $36.4220, with a volume of 867909 sha…
No recent releases where the company itself is speaking.
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.

